APTA Stock Overview
A clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Aptahem AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.16 |
| 52 Week High | SEK 30.00 |
| 52 Week Low | SEK 2.20 |
| Beta | -0.20 |
| 11 Month Change | 4.64% |
| 3 Month Change | 1.94% |
| 1 Year Change | -83.28% |
| 33 Year Change | -97.21% |
| 5 Year Change | -98.79% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| APTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.3% | 3.4% | 1.0% |
| 1Y | -83.3% | 26.3% | 20.6% |
Return vs Industry: APTA underperformed the Swedish Biotechs industry which returned 26.3% over the past year.
Return vs Market: APTA underperformed the Swedish Market which returned 20.6% over the past year.
Price Volatility
| APTA volatility | |
|---|---|
| APTA Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: APTA has not had significant price volatility in the past 3 months.
Volatility Over Time: APTA's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Mikael Lindstam | www.aptahem.com |
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network.
Aptahem AB (publ) Fundamentals Summary
| APTA fundamental statistics | |
|---|---|
| Market cap | SEK 17.90m |
| Earnings (TTM) | -SEK 11.22m |
| Revenue (TTM) | SEK 2.65m |
6.8x
P/S Ratio-1.6x
P/E RatioIs APTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APTA income statement (TTM) | |
|---|---|
| Revenue | SEK 2.65m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 2.65m |
| Other Expenses | SEK 13.87m |
| Earnings | -SEK 11.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 100.00% |
| Net Profit Margin | -424.20% |
| Debt/Equity Ratio | 0% |
How did APTA perform over the long term?
See historical performance and comparison